GET FREE STOCK TIPS WITH LIVE EXECUTIVE SUPPORT CLICK HERE AND JOIN US FREE >> http://www.ripplesadvisory.com/free-trial.php
Shares of Dr. Reddy’s Laboratories added 2 percent intraday Wednesday. The company is planning for phase 2 trial of CA-170.
The company’s wholly owned subsidiary Aurigene Discovery Technologies is planning to initiate a Phase 2 trial of CA-170, a PDL1-VISTA inhibitor to be conducted at sites in India.
CA-170 is an oral small molecule targeting the immune checkpoints PDL1 and VISTA.